Haemonetics revenue rises 8% to $336.2 million; EPS falls to $0.74, guidance reaffirmed
Haemonetics reported first quarter fiscal 2025 results for the period ended June 29, 2024, with revenue up 8.0% to $336.2 million, while GAAP earnings per diluted share fell to $0.74 from $0.80 and adjusted earnings per diluted share fell 2.9% to $1.02. The company reaffirmed its fiscal 2025 revenue, adjusted operating margin, adjusted earnings per share and free cash flow guidance, so shareholders see stronger sales but lower profit in the quarter with no change to the full-year outlook.
Key points
- Revenue was $336.2 million, up 8.0% from the prior year; organic revenue grew 2.8%, with Hospital up 30.7% and Plasma down 2.7%.
- GAAP operating income was $39.8 million, an 11.8% margin, versus $53.7 million and a 17.2% margin a year earlier.
- Operating cash outflow was $27.4 million and free cash outflow was $16.9 million, compared with operating cash inflow of $19.1 million a year earlier.
- Fiscal 2025 adjusted earnings per diluted share guidance of $4.45 to $4.75 was reaffirmed.
The filing
Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 08, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.